EHA Library - The official digital education library of European Hematology Association (EHA)

EFFICACY AND SAFETY RESULTS FROM AN OPEN-LABEL PHASE 2 STUDY OF PARSACLISIB FOR THE TREATMENT OF AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA)
Author(s): ,
Wilma Barcellini
Affiliations:
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,Milan,Italy
,
Irina Murakhovskaya
Affiliations:
Albert Einstein College of Medicine/Montefiore Medical Center Bronx,New York,United States
,
Louis Terriou
Affiliations:
Univ. Lille, Inserm, CHU Lille, Centre de Référence des Maladies Autoimmunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), INFINITE – Institute for Translational Research in Inflammation,Lille,France
,
Fabrizio Pane
Affiliations:
University of Naples 'Federico II',Naples,Italy
,
Andrea Patriarca
Affiliations:
University of Eastern Piedmont and AOU 'Maggiore della Carità',Novara,Italy
,
Kathleen Butler
Affiliations:
Incyte Corporation,Wilmington,United States
,
Susan Moran
Affiliations:
Incyte Corporation,Wilmington,United States
,
Shaoceng Wei
Affiliations:
Incyte Corporation,Wilmington,United States
Ulrich Jäger
Affiliations:
Medical University of Vienna,Vienna,Austria
EHA Library. Barcellini W. 06/09/21; 325445; EP685
Wilma Barcellini
Wilma Barcellini
Contributions
Abstract
Presentation during EHA2021: All e-poster presentations will be made available as of Friday, June 11, 2021 (09:00 CEST) and will be accessible for on-demand viewing until August 15, 2021 on the Virtual Congress platform.

Abstract: EP685

Type: E-Poster Presentation

Session title: Enzymopathies, membranopathies and other anemias

Background
There are no approved therapies for AIHA, a rare acquired condition caused by autoantibody-mediated decompensated destruction of red blood cells. The phosphatidylinositol 3-kinase δ inhibitor parsaclisib has shown efficacy in preclinical models of autoantibody-mediated diseases.

Aims
To describe preliminary 12-week efficacy and safety from an ongoing, multicenter, open-label phase 2 trial (NCT03538041) of parsaclisib in patients with primary AIHA.

Methods
Eligible patients were aged ≥18 years; had a diagnosis of warm AIHA (wAIHA), cold agglutinin disease (CAD), or mixed-type AIHA without an underlying lymphoproliferative malignancy; hemoglobin (Hgb) ≥7–≤10 g/dL; and failure of ≥1 standard therapy. Concomitant use of low-dose corticosteroids (≤20 mg/d prednisone equivalent) was permitted. After providing informed consent, patients received parsaclisib for 12 weeks at a starting oral dose of 1.0 mg once daily (QD; cohort 1) or 2.5 mg QD (cohort 2; enrolled after ≥6 patients with wAIHA in cohort 1 completed 6 weeks). Patients in cohort 1 could have their dose increased to 2.5 mg QD after 6 weeks if they had not achieved meaningful clinical response and/or required transfusions; those in cohort 2 could have dose reductions to 1.0 mg QD for tolerability. Patients achieving clinical benefit could continue to receive parsaclisib in an extension period. Primary endpoints were efficacy (proportion of patients with complete response [CR; Hgb ≥12 g/dL] or partial response [PR; Hgb 10–12 g/dL or ≥2 g/dL increase from baseline] at any visit from Week 6–12) and safety (treatment-emergent adverse events [TEAEs]).

Results
A total of 21 patients (cohort 1, n=10 [8 patients had a dose increase]; cohort 2, n=11) were enrolled and received parsaclisib; 17 patients (81%) completed 12 weeks of treatment. Mean (SD) age was 58.8 (16.6) years; 11 patients (52%) were female and 20 (95%) were White. Fourteen (67%), 4 (19%), and 3 (14%) patients had wAIHA, CAD, and mixed AIHA, respectively, and 6 (29%) had transfusions in the past year. Mean (SD) Hgb at baseline was 9.0 (0.8) g/dL and was similar between cohorts. Overall, 7 patients (33%) achieved CR (cohort 1, n=2 [20%]; cohort 2, n=5 [45%]) and 14 (67%) had PR (cohort 1, n=6 [60%]; cohort 2, n=8 [73%]) at any visit from Week 6 to 12. Dose-dependent increases from baseline in Hgb were observed over time, with cohort 2 (2.5 mg QD) achieving mean Hgb >10 g/dL by Week 2 (Figure). Other hemolytic markers including haptoglobin, reticulocytes, indirect bilirubin, and lactate dehydrogenase trended toward normalization. TEAEs occurred in 18 patients (86%). Five patients (24%) had grade ≥3 TEAEs, with only neutropenia occurring in >1 patient (n=2 [10%]). One patient (5%) had a serious TEAE (hemolytic anemia; deemed unrelated to treatment). Treatment-related AEs (TRAEs) were reported in 6 patients (29%); pruritic rash was the only TRAE occurring in >1 patient (n=2 [10%]), and neutropenia and thrombocytopenia were the only grade ≥3 TRAEs (n=1 [5%] each). TEAEs led to dose interruption in 4 patients (19%) and included neutropenia (n=2 [10%]), diarrhea (n=1 [5%]), and hepatotoxicity (n=1 [5%]; deemed unrelated to parsaclisib). One patient (5%) in cohort 1 discontinued parsaclisib due to a TEAE (thrombocytopenia). There were no fatal TEAEs.

Conclusion
Parsaclisib was generally well tolerated, and treatment resulted in durable normalization of Hgb levels as early as Week 2. Parsaclisib has the potential to be an effective oral treatment for both wAIHA and CAD and warrants further clinical investigation.

Keyword(s): Autoimmune hemolytic anemia (AIHA), Clinical trial, Hemoglobin, PI3K

Presentation during EHA2021: All e-poster presentations will be made available as of Friday, June 11, 2021 (09:00 CEST) and will be accessible for on-demand viewing until August 15, 2021 on the Virtual Congress platform.

Abstract: EP685

Type: E-Poster Presentation

Session title: Enzymopathies, membranopathies and other anemias

Background
There are no approved therapies for AIHA, a rare acquired condition caused by autoantibody-mediated decompensated destruction of red blood cells. The phosphatidylinositol 3-kinase δ inhibitor parsaclisib has shown efficacy in preclinical models of autoantibody-mediated diseases.

Aims
To describe preliminary 12-week efficacy and safety from an ongoing, multicenter, open-label phase 2 trial (NCT03538041) of parsaclisib in patients with primary AIHA.

Methods
Eligible patients were aged ≥18 years; had a diagnosis of warm AIHA (wAIHA), cold agglutinin disease (CAD), or mixed-type AIHA without an underlying lymphoproliferative malignancy; hemoglobin (Hgb) ≥7–≤10 g/dL; and failure of ≥1 standard therapy. Concomitant use of low-dose corticosteroids (≤20 mg/d prednisone equivalent) was permitted. After providing informed consent, patients received parsaclisib for 12 weeks at a starting oral dose of 1.0 mg once daily (QD; cohort 1) or 2.5 mg QD (cohort 2; enrolled after ≥6 patients with wAIHA in cohort 1 completed 6 weeks). Patients in cohort 1 could have their dose increased to 2.5 mg QD after 6 weeks if they had not achieved meaningful clinical response and/or required transfusions; those in cohort 2 could have dose reductions to 1.0 mg QD for tolerability. Patients achieving clinical benefit could continue to receive parsaclisib in an extension period. Primary endpoints were efficacy (proportion of patients with complete response [CR; Hgb ≥12 g/dL] or partial response [PR; Hgb 10–12 g/dL or ≥2 g/dL increase from baseline] at any visit from Week 6–12) and safety (treatment-emergent adverse events [TEAEs]).

Results
A total of 21 patients (cohort 1, n=10 [8 patients had a dose increase]; cohort 2, n=11) were enrolled and received parsaclisib; 17 patients (81%) completed 12 weeks of treatment. Mean (SD) age was 58.8 (16.6) years; 11 patients (52%) were female and 20 (95%) were White. Fourteen (67%), 4 (19%), and 3 (14%) patients had wAIHA, CAD, and mixed AIHA, respectively, and 6 (29%) had transfusions in the past year. Mean (SD) Hgb at baseline was 9.0 (0.8) g/dL and was similar between cohorts. Overall, 7 patients (33%) achieved CR (cohort 1, n=2 [20%]; cohort 2, n=5 [45%]) and 14 (67%) had PR (cohort 1, n=6 [60%]; cohort 2, n=8 [73%]) at any visit from Week 6 to 12. Dose-dependent increases from baseline in Hgb were observed over time, with cohort 2 (2.5 mg QD) achieving mean Hgb >10 g/dL by Week 2 (Figure). Other hemolytic markers including haptoglobin, reticulocytes, indirect bilirubin, and lactate dehydrogenase trended toward normalization. TEAEs occurred in 18 patients (86%). Five patients (24%) had grade ≥3 TEAEs, with only neutropenia occurring in >1 patient (n=2 [10%]). One patient (5%) had a serious TEAE (hemolytic anemia; deemed unrelated to treatment). Treatment-related AEs (TRAEs) were reported in 6 patients (29%); pruritic rash was the only TRAE occurring in >1 patient (n=2 [10%]), and neutropenia and thrombocytopenia were the only grade ≥3 TRAEs (n=1 [5%] each). TEAEs led to dose interruption in 4 patients (19%) and included neutropenia (n=2 [10%]), diarrhea (n=1 [5%]), and hepatotoxicity (n=1 [5%]; deemed unrelated to parsaclisib). One patient (5%) in cohort 1 discontinued parsaclisib due to a TEAE (thrombocytopenia). There were no fatal TEAEs.

Conclusion
Parsaclisib was generally well tolerated, and treatment resulted in durable normalization of Hgb levels as early as Week 2. Parsaclisib has the potential to be an effective oral treatment for both wAIHA and CAD and warrants further clinical investigation.

Keyword(s): Autoimmune hemolytic anemia (AIHA), Clinical trial, Hemoglobin, PI3K

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies